Guth has Friedreich’s Ataxia and chose to raise money at Happy Place Nutrition for Friedreich’s Ataxia Research Alliance ...

The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

On Nov. 4, a 5-year-old Appaloosa mare in Kiowa County, Oklahoma, tested positive for West Nile virus (WNV). The unvaccinated horse developed clinical signs on Oct. 20, including ataxia, loss of ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

Comedian Fiona Cauley talks about turning 29 years old with a Friedreich's ataxia diagnosis, navigating the airport with a ...

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Larimar Therapeutics ( ($LRMR) ) has provided an update. On November 10, 2025, Larimar Therapeutics announced an updated slide presentation ...

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...